Loading…
← CockpitCompetitor Analysis › 0570.HK China Traditional Chinese Medicine Holdings Co. Ltd.Open in the cockpit ↗

China Traditional Chinese Medicine Holdings Co. Ltd.0570.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major
Momentum weak 35
Mkt cap
$716M
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$970,261
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-7.2 pp
WACC 7.2%
Hurdle
n/a
no reverse DCF
Next earnings
121 days
19 Mar 2027
Close · HKDHK$1.13
1D+0.9%
1W-3.0%
1M-5.8%
3M-17.8%
6M-30.7%
YTD-45.9%
1Y-51.9%
ATR %2.9%
52w lowhigh52.9% off high

What China Traditional Chinese Medicine does

Employees: 14,846

China Traditional Chinese Medicine at a glance

Size China Traditional Chinese Medicine (0570.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $716M, the 662nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$1.13 on 18 Nov 2026.

Performance Over six months the shares fell 30.7%, against -10.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue fell 15.8% over the last twelve months (peer median +3.9%); the operating margin is 0.0% (peer median 9.7%).

Valuation It trades at 0.3× enterprise value to sales against a peer median of 2.1× (cheapest of 19).

Capital Return on invested capital runs 7.2 points below its cost of capital (7.2% WACC).

Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 920570.HK 70
Six months, rebased to 100: China Traditional Chinese Medicine against the median of its 20 peers (local-currency closes).

China Traditional Chinese Medicine financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$14.2BHK$16.0BHK$17.9BHK$20.0BHK$16.6B
Revenue growth—-11%-11%+20%—
Gross profitHK$6.73BHK$7.69BHK$8.52BHK$10.2BHK$8.37B
EBITDAHK$1.25BHK$1.58BHK$1.95BHK$2.50BHK$2.47B
Net income-HK$1.14B-HK$371MHK$58.6MHK$1.42BHK$889M
Free cash flowHK$1.63BHK$1.67BHK$2.84BHK$1.25BHK$43.6M
Capital expenditureHK$296MHK$352MHK$555MHK$540MHK$613M
Total debtn/aHK$2.78BHK$4.27BHK$5.68BHK$5.66B

Quarterly statements and history in the cockpit →

China Traditional Chinese Medicine competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%-10%0%4534603998SGMT688799600530688566600829NVCT218630070549850009156004792171002907002424600351688658PHIL6884880570.HK6-month return →1-month return →
Up and to the right = strong over both horizons. China Traditional Chinese Medicine is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×10×20×30×45346039986887996005306008293007050009152171002907PHIL6884880570.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. China Traditional Chinese Medicine is the large dot.

China Traditional Chinese Medicine competitors and peer comparison

How China Traditional Chinese Medicine compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

China Traditional Chinese Medicine against its 20 peers (data as of 18 Nov 2026)
Measure0570.HKPeer medianRank in peer set
1-month return-5.8%-8.4%10th highest of 21
6-month return-30.7%-10.1%7th lowest of 21
Distance from 52-week high-52.9%-34.0%4th lowest of 21
Revenue growth (TTM)-15.8%+3.9%3rd lowest of 19
Operating margin0.0%9.7%4th lowest of 19
EV / Sales0.3×2.1×cheapest of 19
ROIC minus cost of capital-7.2 pp+1.5 pp2nd lowest of 17
EV / EBITDA3.8×4.7×3rd cheapest of 5
Net debt / EBITDA-3.0×-1.2×least indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%0.3×n/an/a
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%0.8×n/an/a
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%2.6×-4.8%+6.4%
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%3.9×n/an/a
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%16.1×42.7%-0.9%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%3.8×5.9%+11.3%
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%0.6×4.0%+5.3%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%1.1×-11.8%+1.9%
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%1.8×-2.0%+26.1%
Earth 4985.TJapan$687M+7%+4%4%0.5×-1.6%-1.8%
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%2.5×n/an/a
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%1.4×-2.1%0.0%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%5.3×9.4%-1.4%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%2.5×13.5%-0.2%
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%1.6×-8.3%-2.8%
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%1.7×n/an/a
Philogen PHIL.MIItaly$672M-11%+295%79%0.9×n/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%6.7×31.9%+19.8%

Questions

Which companies are China Traditional Chinese Medicine's closest peers?
The cockpit's peer set: Mochida Pharmaceutical (4534.T), Hunan Fangsheng Pharmaceutical (603998.SS), Sagimet Biosciences (SGMT), Hunan Warrant Pharmaceutical (688799.SS), Shanghai Jiaoda Onlly (600530.SS), Jiangsu Jibeier Pharmaceutical (688566.SS), HPGC Renmintongtai Pharmaceutical (600829.SS), Nuvectis Pharma (NVCT).
Is China Traditional Chinese Medicine expensive compared with its peers?
On ev / sales it trades at 0.3× against a peer median of 2.1×, cheapest of 19 in its peer set.
How has China Traditional Chinese Medicine stock performed?
Over six months to 18 Nov 2026 the shares returned -30.7% against -10.1% for the median peer; over one year -51.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.